Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

AbbVie

Amgen

Bristol-Myers

Fidelity MSCI Health Care ETF

Gilead Sciences

iShares U.S. Healthcare ETF

Johnson & Johnson

Pfizer

Thermo Fisher Scientific

UnitedHealth Group

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.

Healthcare ETFs in Focus as Q2 Earnings Unfold

Merck (MRK)/Bayer's (BAYRY) vericiguat gets approval for symptomatic chronic heart failure in patients with reduced ejection fraction in Europe.

Merck (MRK) Heart Failure Drug Verquvo Gets Approval in Europe

Merck has suffered considerably during COVID.

An Improving Outlook For Merck

Baxter

Cigna

Cisco Systems

Chevron

D.R. Horton

Gaming and Leisure Properties

Barrick Gold

Intel

Lowe's

PepsiCo

Raytheon Technologies

Exxon Mobil

Kiplinger Investing publishes opportune buy-lists for investors online. Two billionaire stock-lists by Dan Burrows included 50 published 12/8/20, with 30 more out June 1, 2021. Seventeen were duplicated, leaving 63. 41 of these 63 billionaire-held stocks pay dividends. As of 7/20/21, the top-ten ranged 2.52%-6.22% by annual yield and ranged 23.13%-52.70% per broker-estimated price-target upsides.

Pre-August Billionaire Flash: 63 Stocks, 41 Dividends, 3 Buys

KENILWORTH & WOODCLIFF, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma

FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma

At its current price levels, investment in Merck & Co. represents a wide moat business for sale at a discounted price.

Merck & Co.: A Wide Moat Business At A Discounted Price

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--VERQUVO® (vericiguat) Approved in the European Union - European Approval Granted to Bayer Marks Another Important Milestone for VERQUVO

VERQUVO® (vericiguat) Approved in the European Union

The U.S. FDA approved a new version of Merck's (NYSE:MRK) pneumococcal vaccine that prevents invasive disease caused by 15 strains of bacteria called Streptococcus pneumoniae.

Company Of The Day: Merck

Merck & Co Inc (NYSE: MRK) has announced new data from Phase 2a trial evaluating islatravir for pre-exposure prophylaxis (PrEP) of HIV-1 infection in adults at low risk of contracting HIV-1.  After 24 weeks, once-monthly oral islatravir was generally well tolerated versus placebo.

Merck Discloses New Islatravir Data Supporting Safety Profile For PrEP Regime For HIV Infection

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Presents New Data from Ongoing Phase 2a Clinical Trial Investigational, Once-Monthly, Oral Islatravir for HIV-1 Prevention at IAS 2021

Merck Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Investigational, Once-Monthly, Oral Islatravir for HIV-1 Prevention at IAS 2021

Merck's (MRK) 15-valent pneumococcal conjugate vaccine, Vaxneuvance includes pneumococcal serotypes, 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

Merck (MRK) Gets FDA Nod for Pneumococcal Vaccine Vaxneuvance

For the second time in five weeks, the FDA has approved a new pneumococcal conjugate vaccine, this time giving the nod to a shot from Merck & Co Inc (NYSE: MRK). The vaccine, Vaxneuvance, is designed to protect against 15 strains of pneumococcal bacteria.

Merck's Pneumococcal Vaccine Lands FDA Nod, Just Few Weeks After Its Rival

Caterpillar

Direxion Daily S&P Oil & Gas Exp. & Prod. Bear 2X Shares

Direxion Daily Energy Bear 2X Shares

BMO REX MicroSectors FANG+ Index -3X Inverse Leveraged ETN

FuboTV

Honeywell

McDonald's

Microsoft

MicroSectors U.S. Big Oil Index -3X Inverse Leveraged ETNs

Direxion Daily 20+ Year Treasury Bull 3X Shares

Direxion Daily Small Cap Bear 3x Shares

Direxion Daily Utilities Bull 3X Shares

Visa

Utilities Select Sector SPDR Fund

Two new sample breakout stocks for Week 29 with better than 10% short-term upside potential. New ETF/ETN forecast section has been added. This past week the peak gains were in ATOS +26.6% and FUV +5.8% with Market and S&P 500 Momentum Gauges in extremely high negative warning conditions.

Week 29 MDA Breakout Stocks - July 2021: Short-Term Stocks And Funds To Give You An Edge

General Dynamics

Home Depot

Illinois Tool Works

Lockheed Martin

SPDR S&P 500 ETF Trust

Texas Instruments

This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for your consideration. To rank stocks, I use DVK Quality Snapshots to obtain quality scores, sort them in descending order, and break ties with additional metrics.

10 Dividend Growth Stocks For July 2021

The market may be underappreciating the long-term prospects of Johnson & Johnson and Merck.

2 Top Pharma Stocks to Buy Right Now

Apple

Hexavest of Montreal reduced positions in Apple and Microsoft stock, and increased holdings in Pfizer and Merck in the second quarter.

Big Contrarian Investor Sold Apple, Microsoft Stock, Bought Pfizer and Merck

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces US FDA Approval of VAXNEUVANCE™ for Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes

Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes

American Express

Bank of New York Mellon

Globe Life Inc

Kraft Heinz

Coca-Cola

Mastercard

Sirius XM Holdings Inc

STORE Capital

U.S. Bancorp

Verizon

This Buffett holdings list from Kiplinger first appeared 5/17/21 on line. YCharts and Dogs of The Dow also track this Buffett/Berkshire Batch. Here is your update from 7/13/21 YCharts data. 8 of 46 current Berkshire Hathaway owned stocks pay dividends. As of 7/13/21 the top ten ranged 2.72%-5.16% by annual yield and ranged 19.87%-67.17% per broker estimated price target upsides.

Buffett 46 July Holdings Include 28 Dividend Payers

Merck & Co Inc (NYSE: MRK) has announced positive event-free survival (EFS) data from the pivotal neoadjuvant/adjuvant Phase 3 study KEYNOTE-522 trial of Keytruda (pembrolizumab) in breast cancer.  The trial investigated neoadjuvant (delivered before the primary treatment) Keytruda, plus chemo followed by adjuvant Keytruda as monotherapy (Keytruda regime) compared with neoadjuvant chemotherapy followed by adjuvant placebo in patients with high-risk early-stage triple-negative breast cancer (TNBC).

Merck Touts Encouraging Event-Free Survival For Keytruda Regime Over Placebo-Chemo Regime In Breast Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus Chemo Before Surgery and Cont'd as Single Agent Showed Stat Sig Event-Free Survival vs Neoadjuvant Chemo in High-Risk Early-Stage TNBC

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival (EFS) Result Versus Neoadjuvant Chemotherapy Alone in High-Risk Early-Stage TNBC

News for Merck Stock (MRK)